Vulvovaginal atrophy, now known as the genitourinary syndrome of menopause (GSM), occurs with the decline of estrogen in the menopausal period. As with many clinical conditions, the spectrum of GSM requires the clinician to consider the effect on the patient’s quality of life. Although many symptoms are pacified effectively with situational lubricants and regular moisturizers, local estrogen is a safe, effective, and affordable way to treat the vulvovaginal changes of menopause.
In a randomized, double-blind, sham-controlled study of infants with spinal muscular atrophy (SMA) type 1, nusinersen treatment led to significant improvement in motor milestones and survival without significant adverse reactions. A safety trial of gene therapy for SMA type 1 demonstrated prolonged ventilator-free survival and improved motor milestones with minimal side effects.
About 32 million postmenopausal women in the United States are affected by vulvar and vaginal atrophy, which can cause painful sexual activity and urination, as well as vaginal dryness, itching, and irritation. Recent data presented at ENDO 2016, the annual meeting of the Endocrine Society, suggests an investigational low-dose vaginal estrogen capsule may help relieve such symptoms.